Dr Reddy’s

Dr. Reddy's Laboratories announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for…

Dr. Reddy’s Laboratories, a global pharmaceutical company, announced the launch of its oral semaglutide biosimilar, indicated for…

Dr. Reddy’s Laboratories announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus…

The company outlines near-term and long-term emission reduction goals across its value chain

Dr. Reddy’s Laboratories announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…

Dr. Reddy’s Laboratories announced the launch of the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in…

Dr. Reddy’s, a global pharmaceutical company has announced the completion of a definitive transaction with Johnson & Johnson,…

Dr Reddy’s Laboratories, Emcure Pharma, Hetero Drugs and Mylan Labs (a subsidiary of Viatris), are among the six companies that…

Dr Reddy's Rituximab biosimilar DRL_RI (ITUXREDI) progresses towards European approval with EMA CHMP endorsement

Dr Reddy’s gets exclusive commercialisation rights of denosumab in the US as well as semi-exclusive rights in Europe and UK